Lucía Sánchez-Peña

8PUBLICATIONS
29CO-AUTHORS
Medical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Microbial geneticsMedical bacteriologyMicrobial ecology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 30, 2026
Relative inhibitory activities of taniborbactam and xeruborbactam against KPC variants conferring reduced susceptibility or resistance to ceftazidime/avibactam, cefiderocol, and cefepime/taniborbactam.

|Aug 19, 2026
In vivo emergence of ceftazidime/avibactam resistance in Pseudomonas aeruginosa driven by OXA-1381, a novel W157L Ω-loop variant of OXA-2.

|May 29, 2026
Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales.

|May 29, 2026
Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa.

|Mar 27, 2026
Emergence of KPC-producing Pseudomonas aeruginosa in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam.

Gloria Pérez-Rodríguez, Pablo Aja-Macaya, Lucía González-Pinto

|Oct 21, 2025
Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa.

Lucía González-Pinto, María Antonia Gomis-Font, Gloria Pérez-Rodríguez

Pageof 2

Frequent Collaborators

8 joint publications

Lucía González-Pinto

8 joint publications

Tania Blanco-Martín

8 joint publications

Jorge Arca-Suárez

8 joint publications

Germán Bou